Merck Provides Update on Odanacatib Development Program

Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck ’s investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use.Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orInvestors:Teri Loxam, 908-740-1986Ticker Slug:Ticker:MRKExchange:NYSEread more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK NYSE:MRK odanacatib Source Type: news